Short- and long-term outcomes of children with cyclic vomiting syndrome

Insights

Amitriptyline showed better results than propranolol for treating cyclic vomiting syndrome (CVS) in children. Many children with CVS experience favorable long-term outcomes, especially those who respond well to initial prophylactic treatment.

Area of Science:

  • Pediatric Gastroenterology
  • Pharmacology
  • Clinical Outcomes Research

Background:

  • Cyclic Vomiting Syndrome (CVS) is a debilitating condition in children.
  • Effective prophylactic pharmacotherapy is crucial for managing CVS.
  • Understanding treatment efficacy and long-term outcomes is essential for clinical practice.

Purpose of the Study:

  • To evaluate the efficacy of prophylactic pharmacotherapy for pediatric cyclic vomiting syndrome.
  • To assess both short-term and long-term outcomes in children with CVS.
  • To compare the effectiveness of different prophylactic medications.

Main Methods:

  • Retrospective review of medical records for 32 children diagnosed with CVS (2000-2013).
  • Classification of treatment response as 'good' or 'no response' after 3-6 months.
  • Long-term outcome assessment based on episode frequency over the past year for patients diagnosed for ≥2 years.

Main Results:

  • Amitriptyline demonstrated a significantly higher good response rate (73%) compared to propranolol (36%, p=0.04) at 3-6 months.
  • Among 19 patients with long-term follow-up (mean 6.3 years post-diagnosis), 74% achieved favorable outcomes (excellent or good).
  • A strong correlation was observed: 86% of children with favorable long-term outcomes showed a good initial response to prophylactic medication.

Conclusions:

  • Amitriptyline may be more effective than propranolol for CVS prophylaxis in children.
  • Children with CVS generally experience favorable long-term outcomes.
  • Early positive response to prophylactic medication predicts better long-term prognosis, warranting further randomized controlled trials.
Abstract

Related Concept Videos

Pathophysiology of Vomiting01:22

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
4.4K
Pyloric Obstruction01:11

Pyloric Obstruction

Pyloric obstruction, also referred to as gastric outlet obstruction, is a condition characterized by narrowing or blockage at the pylorus—the muscular valve regulating the flow of stomach contents into the duodenum. When this passage becomes impaired, the stomach cannot effectively empty its contents into the small intestine. This disruption leads to a range of gastrointestinal symptoms, including early satiety, bloating, epigastric pain, postprandial nausea, persistent vomiting, and...
2
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
912
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
788
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.2K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.2K